Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Clinical Trial of Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators to Reverse Tumor Hypoxia and Immune Dysfunction in Solid Tumor Malignancies

Next Previous
Search
Trial Profile

A Phase II Clinical Trial of Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators to Reverse Tumor Hypoxia and Immune Dysfunction in Solid Tumor Malignancies

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Metformin (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Rosiglitazone (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 14 Jul 2023 Planned End Date changed from 1 Dec 2029 to 30 Apr 2032.
    • 14 Jul 2023 Planned primary completion date changed from 1 Dec 2028 to 30 Apr 2032.
    • 05 Apr 2023 Planned number of patients changed from 108 to 72.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top